Shots:
- AstraZeneca to acquire AbelZeta’s 50% stake in the China development & commercialization rights to C-CAR031, securing full global rights to develop, manufacture, & commercialize C-CAR031 worldwide
- Under a prior agreement, AstraZeneca secured global rights to develop, manufacture, & commercialize C-CAR031 outside China, while AbelZeta remains eligible for additional development milestones & royalties tied to rest-of-world development
- As per the deal, AbelZeta is eligible to receive up to $630M from AstraZeneca, incl. an upfront & development, regulatory, & commercial milestones payments for the GPC3 program in China
Ref: PRnewswire | Image: AstraZeneca & AbelZeta | Press Release
Related News: Jacobio Pharma Forge ~$2B+ Partnership with AstraZeneca for JAB-23E73
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
